Healthcare Businesses for Sale and Investment Opportunities

- Doctor specializing in Pharmacology with 20+ years of experience in healthcare in the US and Saudi, planning to acquire a well established hospital. - He is running a business in same industry and is also a research specialist in pharmacology department in a prestigious university in Saudi. - The hospital, located under the royal commission in Riyadh, operates in the healthcare industry and has a diverse clientele, offering robust revenue streams and is accredited by recognized industry bodies. Has been running for 20+ years. - With experienced promoters and strong partnerships, the hospital is planning an expansion from 50 to 100 beds, aiming to enhance its multi-specialty services, including general surgery, cardiology, ophthalmology, and all major specialties. - The hospital is equipped with state-of-the-art facilities including OT, ICU, pharmacy, consultations, lab facilities, imaging, and parking, as well as staff quarters. - The business employs 300 permanent employees, in addition to contract employees, and has all the necessary licenses to operate in the healthcare industry. - The hospital has 75 permanent doctors and 55 visiting doctors, and has been recognized as an award-winning healthcare provider and innovator in the industry. - The business has experienced a high growth rate from SAR 125 million last year to SAR 240 million this year with 25% EBITDA margins, attributes to the improvisation and addition of facilities resulting in increased client flow. - With its trusted reputation, expansion plans, and commitment to exceptional patient care, the hospital presents an attractive investment opportunity in the healthcare sector.

- New Zealand based company in the process to start a 5-star luxury cruise ship based long-term old age care residence. - The facility will have a global international customer base of over 550 elderly HNWI, VHNWI, and UHNWI full-time residents per ship. - Business has burgeoning growth rate projections, scaleable and global from day one. The niche market is untapped and to secure first-to-market advantages with economic and physical moats for the next 2-7 years. - Several strategic partner MOUs already in place, with the necessary industry business expertise on the board of advisors to ensure the success of the business model. - We will have a bespoke high-end brand which includes beauty salons and multiple life-enhancing programs for our residents. - We have already finalized the ship we wish to buy and waiting for the investment. - Company does not have any liability. - Business is 100% owned by 2 directors who are husband and wife. - Promoter has over 10 years of experience in this field. - Our residence will have a refundable accommodation deposit per luxury stateroom is currently at USD 65,000 per sqm, and the daily rate per resident will be USD 550 per day for services, and an a la carte menu for luxury items, additional medical and hospitality services,

- Pharmaceutical business located in Dhaka, Bangladesh, has a rich history of 52 years in the industry, having recently been acquired by new management. - The brand, licenses, registrations, client base, and property have been transferred to the new owners. - Was supplying across Bangladesh, the Middle East, and African countries under its own branding. - The business was temporarily closed down three years ago due to personal reasons, but it is now in the process of re-establishing existing contracts and resuming production. - With 43 patents from medical authorities and various licenses including drug manufacturing, IRC, and Export & Import, the company has a strong foundation for pharmaceutical production and distribution. - The pharmaceutical company manufactured a diverse range of drug formulations, including liquid, capsule, tablet, suspension, syrup, injection, aerosol spray & inhaler, injections, bolus, premix powder, premix solutions, and bulk drugs. - Manufactured drug categories include - antibiotics, antibacterials, chemotherapeutics, antiprotozoals, antidiarrhoeal, antidiabetic, antihistamines, NSAIDs, antihypertensives, multivitamins etc. - The company possesses a broad client base, serving wholesalers, pharmacies, hospitals, clinics, and distributors, indicating its reach and potential for growth in both domestic and international markets. - Revenue will be primarily generated through the sale of generic medications, with a focus on cost-effective production and competitive pricing strategies, positioning the business well for market success. - The company is led by experienced professionals with a background in pharmaceutical manufacturing, research, and business management, indicating strong leadership and expertise within the organization. - Had established strong relationships with suppliers of raw materials, regulatory authorities, distribution partners, and healthcare institutions. Have started re-establishing existing contracts and will restart the supply. Will continue to manufacture under the existing brand. - Additionally, the current owners are into manufacturing and supplying medical equipment to hospitals and healthcare facilities, thereby providing an opportunity to establish new contracts.

- Company does business on Advanced Stem Cell technologies such as hypoxic stem cell tech, immunomodulation tech, and advanced cancer stem cell technology, - Our services include clinical stem cell protocol services, stem cell procedures, stem cell education, consultancy and comprehensive establishment of stem cell centres including advanced stem cell laboratories - for hospital, industrial, and clinical services. - Founder is a stem cell scientist with over 20 years of experience in the industry. - We provide advanced stem cell technology transfers, therapy consultancy, stem cell therapy technology, stem cell academic services, advanced stem cell laboratory erections, platforms and applications. - Have trained more than 100 doctors, Scientists and professors in Stem Cell field across the world. - Established and Delegated Technologies for 6 Units (including for foreign establishments)

- API manufacturing unit in Telangana operational for the last 4 years. - This is a USFDA and EU regulation-compliant manufacturing facility. - The factory is used for contract manufacturing of APIs. - The buyer gets all the tangible and intangible assets of the factory.

- The company focused on manufacturing dental materials used by dental technicians. - Based in Slovenia and primarily engages in business-to-business (B2B) model. - The business supplies its products to pharmaceutical distributors, with a network of 200 distributors across Slovenia. - Receives an average of 150-200 orders per month. - The company holds several licenses and certifications, including MDR, ISO, and FDA approvals. - It has a global presence, selling its products in over 65 countries through its distributor network. - The company has established long-term partnerships with its customers. - The business prides itself on its stable medical production and holds all necessary certificates, providing a solid foundation for its operations and products. - There are 155 permanent employees, who are handling various segments of business operations. No additional contract/temporary employees are required.

- Business primarily focused on gene therapy and biomarker/diagnostic services, with a specific emphasis on neurological conditions such as ALS, Parkinson's, Alzheimer's, and TBI. - Offers biomarker testing as a CRO for pharma and researchers. Additionally, it is involved in the development of Adeno-Associated Viruses (AAVs) for neurodegenerative disorders, with a particular focus on inflammation and targeting neurons and glial cells. - Has patented and licensed technologies from premier research institutions. - The company generates revenue on a per research project basis, with an average project duration of 3 months and an average value ranging from $8,000 to $25,000. It has successfully completed projects for 10 different research companies since its inception. - The company is currently engaged in a gene therapy research project involving 2,600 samples. - There are 2 permanent employees, additionally, we have a few temporary employees/interns as well.

- A profound blueprint positioned to have a powerful impact on the medical and IT space. - Approximately 9.3 million doctors, hospitals, nursing homes, and medical supply companies have already been identified as a global target market, with vertical potential. - These soon-to-be ironclad trademarks mitigate the risk of this substantial outlay, and the concept is in the process of separating into its own entity. - The numbers provided are open to discussion, and the sales structure is flexible, including partnerships or outright sale. - As a digital service, benefits investors situated anywhere in the world. - This robust concept will quickly gather tailwinds, with end-user budgets pivoting to provide exponential growth. - Only trailblazers and visionaries will appreciate the value of this transformational proposition. - Minimum return of $150 million yearly. - An extensive presentation is available.